Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Kavanagh (London, United Kingdom), C. Roxas (London, United Kingdom), L. Green (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Thomson (London, United Kingdom), V. Payne (London, United Kingdom), A. Hearn (London, United Kingdom), B. Kent (London, United Kingdom), G. D'Ancona (London, United Kingdom), J. Dhairwal (London, United Kingdom), A. Nanzer (London, United Kingdom), D. Jackson (London, United Kingdom). Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma. 2257

Member's Comments

No comment yet.

Related content which might interest you: Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena Source: Eur Respir J, 56 (4) 2000117; 10.1183/13993003.00117-2020 Year: 2020 Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Age is a predictor of efficacy of monoclonal antibodies in allergic severe asthma Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses Year: 2019 Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 A monoclonal antibody to IL-1B attenuates the late asthmatic response to antigen challenge in patients with mild asthma Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006 Effect of treatment with anti-IgE antibody on airway inflammation in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Antinuclear antibodies and severe evolution of asthma Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007 Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007 Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005 Management of severe allergic asthma in the UK: Which monoclonal antibody would you choose? Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Serum level of specific IgG antibody for aspergillus and its association with severity of asthma in asthmatic children Source: Annual Congress 2012 - Clinical and diagnostic markers and management of paediatric allergic diseases Year: 2012 Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 The importance of quantifying serum antibody associated with allergic alveolitis Source: Eur Respir J 2004; 24: Suppl. 48, 355s Year: 2004 Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 MEMP1972A, an anti-M1 prime monoclonal antibody, reduces serum IgE in healthy and allergic rhinitis subjects Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Improved small airway function by benralizumab in patients with severe eosinophilic asthma Source: Virtual Congress 2020 – From respiratory physiology to clinical practice: exercise and respiratory muscles Year: 2020 Immunological intervention with anti-immunoglobulin-E antibody to prevent asthma exacerbations Source: Eur Respir J 2001; 18: 249-250 Year: 2001